b'Screening and Management\nof\nAsymptomatic Renal Stones\nin Astronauts\nDavid Reyes, MD, MPH1,2,3, James Locke, MD, MPH1,\nAshot Sargsyan, MD1,3, and Kathleen Garcia, RDMS1,3\n1 NASA\n\n\xe2\x80\x93 Johnson Space Center, Flight Medicine Clinic\n2 University of Texas Medical Branch at Galveston, Aerospace Medicine\n3 KBRwyle, Houston, Tx\n\n88th Annual Aerospace Medical Association Meeting, 2017 \xe2\x80\x93 Denver, Colorado\n\nDisclaimer\n\xe2\x80\xa2 No off label uses\n\xe2\x80\xa2 No conflicts of interest\n\nOverview\n\xe2\x80\xa2\n\xe2\x80\xa2\n\xe2\x80\xa2\n\xe2\x80\xa2\n\xe2\x80\xa2\n\nAnatomy and pathology\nEpidemiology\nScreening\nManagement\nWaiver\n\nGeneral Population\n\xe2\x80\xa2\n\n\xe2\x80\xa2\n\nLifetime prevalence 10% male, 5% female\n\xef\x82\xa7 Increasing incidence (20 - 74 y.o.)\n2\n3.7% to 4.6% of commercial aviation pilots\n\n1. Hall, P. (2009) Nephrolithiasis: Treatment, causes and prevention, Clev Clin J Med, 76(10):583-591\n2. Hyams, E., et al. (2011) The incidence of urolithiasis among commercial aviation pilots, J Urol, 186:914-916.\n\nMineralized Renal Material (MRM)\n\xe2\x80\xa2 Small areas of calcification found incidentally\n\xe2\x80\xa2 Of uncertain significance\n\xe2\x80\xa2 We need to characterize MRM\n\xef\x82\xa7\n\nHow common?\n\n\xef\x82\xa7\n\nDo they turn into stones or disappear with time?\n\n\xef\x82\xa7\n\nIs spaceflight a risk factor for clinical stones?\n\nScreening Needs\n\xe2\x80\xa2 Management of MRM/stone has varied widely\n\xe2\x80\xa2 Unknown how many astronauts have MRM\n\xe2\x80\xa2 Understanding is important for future missions\n\nScreening Needs\n\xe2\x80\xa2 Periodic screening \xef\x83\xa0 Annual exams\n\xe2\x80\xa2 Low or no radiation \xef\x83\xa0 Ultrasound\n\xe2\x80\xa2 Standardized methodology \xef\x83\xa0 Ultrasound review panel\n\xe2\x80\xa2 Standardized management \xef\x83\xa0 A clinical practice guideline\n\nWhen to Screen?\n\nUltrasound Benefits\n\xe2\x80\xa2 Low cost\n\xe2\x80\xa2 No radiation\n\xe2\x80\xa2 Easy to do\n\xe2\x80\xa2 Easy to repeat\n\xe2\x80\xa2 Minimal time commitment for astronauts\n\nNatural History\nSize (mm)\n\nStone Free\n\nProgression\n\nIntervention\n\n<= 5\n\n28%\n\n40.4%\n\n5.3%\n\n5 - 10\n\n4.8%\n\n52.4%\n\n9.5%\n\n>= 10\n\n0%\n\n71.4%\n\n14.3%\n\nKoh et al. (2011), Outcomes of long-term follow-up of patients with conservative management of asymptomatic renal caliculi, BJU Int, 109:622-625.\n\nSpontaneous Passage vs. Stone Size\nThe Sweet Spot!\n\nUeno et al. (1977), Relation of spontaneous passage of ureteral calculi to size, Urology, 10(6):544-546\n\nEnhanced U/S Protocol\n1. Echogenic\n\n\xef\x83\xa0 seen from 2 or more angles\n\xef\x83\xa0 opaque to ultrasound\n\n2. Shadowing\n3. Twinkling\n\n\xef\x83\xa0 twinkling in Doppler mode\n\n4. Dispersion\n\n\xef\x83\xa0 spectral frequency dispersion\n\n5. Measurable\n6. Location\n\n\xef\x83\xa0 >3 mm\n\n\xef\x83\xa0 parenchymal, papillary or collecting system\n\nEnhanced U/S Protocol\n\xe2\x80\xa2\n\nStandardized and systematic screening\n\n\xe2\x80\xa2\n\nMultiple scanning positions\n\n\xe2\x80\xa2\n\nMultiple probe views\n\n\xe2\x80\xa2\n\nVarious ultrasound modes\n\nClinical Practice Guideline\n\xe2\x80\xa2\n\nAnnual ultrasound for all active astronauts\n\n\xe2\x80\xa2\n\nUse of specialized ultrasound protocol\n\n\xe2\x80\xa2\n\nSuspicion for stone \xef\x83\xa0 Low-dose, high resolution CT\n\n\xe2\x80\xa2\n\nStone by CT \xef\x83\xa0 Flexible Ureteroscopy preferred\n\n\xe2\x80\xa2\n\nMission assignment affects treatment method\n\n\xe2\x80\xa2\n\nPotential waivers for very small, stable MRM\n\nUS Navy Standards\n\xe2\x80\xa2\n\nWaivers given for...\n\xef\x82\xa7 calcium oxalate, calcium phosphate, uric acid and\nstruvite;\n\xef\x82\xa7 retained stones in the renal parenchyma;\n\xef\x82\xa7 recurrent stones > 12 months apart.\n\n\xe2\x80\xa2\n\nMedical evaluation & urology consult required\n\nUS Navy Standards\n\xe2\x80\xa2\n\nWaivers NOT given for...\n\xef\x82\xa7\n\nrecurrent stones within one year\n\n\xef\x82\xa7\n\ncysteine stones\n\n\xef\x82\xa7\n\nhypercalcuria\n\n\xef\x82\xa7\n\nstones retained in the collecting system\n\nWhere we are\xe2\x80\xa6\n\xe2\x80\xa2\n\n\xe2\x80\xa2\n\xe2\x80\xa2\n\nAll active astronauts have been screened\n\xef\x82\xa7 4 were post-flight\nSeven renal panel meetings done\nPrelim results to NASA-AMB Summer 2017\n\nTreatment During a Mission?\nUreteral Stone Size and Time to Passage\n\nMiller and Kane (1999), Time to stone passage for observed ureteral calculi: A guide for patient education, J. Urology, 162:688-691.\n\nReyes, D, Garcia, K, Sargsyan, A, & Locke, J, Screening and Management of\nAsymptomatic Renal Stones in Astronauts, in preparation, to be submitted to\nAMHP, May 2017.\n\nThank you.\nDavid Reyes\ndpreyes@utmb.edu\n\nSensitivity (%)\n\nSpecificity (%)\n\nDose (mSv)\n\nUltrasound\nAverage 2.6 mm (1 \xe2\x80\x93 9 mm, SD 1.15 ), n = 51 pts, 114 stones [17]\nShadowing alone\n\n65 (PPV 90)\n\n-\n\n0\n\nTwinkling alone\n\n81 (PPV 94)\n\n-\n\n0\n\nShadowing + Twinkle\n\n88 (PPV 96)\n\n-\n\n0\n\nAverage 3.9 mm ( 1-20 mm), n = 105 pts, 65 stones, CT as reference [18]\nShadowing alone\n\n48 (PPV 81)\n\n99\n\n0\n\nShadowing + Twinkle\n\n55 (PPV 67)\n\n99\n\n0\n\n45 - 58\n85\n\n69 - 77\n90\n\n0.7\n3\n\n97\n\n95\n\n3\n\n95 \xe2\x80\x93 98\n\n96 - 98\n\n10\n\nX-Ray\nKUB\nIVP\nCT\nLow-dose, non-con.\nNon-contrast\nMRI\n93 - 100\n\n95 - 100\n\n0\n\n'